Clinical trial
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride…
NCT00190775 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190775 |
|---|---|
| Title | A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Official title | A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine Hydrochloride, Placebo |
| Enrollment | 502 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 22, 2011 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: